short-term investments decreased. As the growth rate of total revenue was lower than the growth rate of total expenses, then the Net profit attributable to Equity holders of the Company in Q2/2018 and of
49.34 17.69% Finance cost 49.11 68.10 18.99 38.67% Income tax expenses 48.04 57.52 9.48 19.73% Net profit 181.71 202.58 20.87 11.49% Net profit ratio (ROS) 17.16% 15.74% Earnings per share (Baht) 0.34
67.37 94.72 27.35 40.60% Income tax expenses 59.19 65.40 6.21 10.49% Net profit 227.68 252.81 25.13 11.04% Net profit ratio (ROS) 16.00% 14.78% Earnings per share (Baht) 0.37 0.42 0.05 13.51% Total
to the decreasing in the selling weight and the overall selling price as well. Eventually, there were the impacts to the lower gross profit in the current quarter as well. For nine months ended 31st
period was declined when comparing to the same period of the previous year. However, the Company and its subsidiaries were able to resume their net profit in the current quarter compared to the first
. 49% 3. Mr. Apichart Kasemkulsiri 1% 4. Mrs. Ornruedi Na-Ranong 1% Source of Funding: Cash flow from business operation of the Company Profit of Investment: Dividend The above is not within the scope of
%) Gross Profit 192.41 39.9% 237.71 45.4% 45.30 23.5% SG&A 82.75 17.2% 97.39 18.6% 14.64 17.7% EBITDA 155.43 32.2% 186.69 35.7% 31.26 20.1% EBIT 109.66 22.7% 140.33 26.8% 30.67 28.0% Interest Expenses (0.80
, decrease Baht 0.59 million or 6.08%, both period not very difference. 2. Cost of sale , Profit margin In Q3/2017 the company had cost of sale Baht 85.71 million compare with the same period of previous year
%) and IPD (10%). This promising growth was due to more subspecialties, more Operation : Consolidated Profit & Loss Statement 2Q 2Q % 6 mth 6 mth % Unit : THB million 2019 2018 change 2019 2018 change